Efficacy Of Single Dose Rituximab and Mycophenolate Versus Two Doses Rituximab in Children with Steroid Dependent and Frequent Relapsing Nephrotic Syndrome: Randomized Open-Labeled Pilot Trial Read more about Efficacy Of Single Dose Rituximab and Mycophenolate Versus Two Doses Rituximab in Children with Steroid Dependent and Frequent Relapsing Nephrotic Syndrome: Randomized Open-Labeled Pilot Trial
Effect of Gum Arabic supplementation on butyrate, uremic retention molecules and inflammation in chronic kidney disease patients Read more about Effect of Gum Arabic supplementation on butyrate, uremic retention molecules and inflammation in chronic kidney disease patients
Early administration of Tocilizumab in Immunocompromised and potential high-risk patients for developing COVID-19 Read more about Early administration of Tocilizumab in Immunocompromised and potential high-risk patients for developing COVID-19
Autologous Bone marrow derived osteoblasts in the Management of Avascular Necrosis of the Head of Femur: A Phase II Read more about Autologous Bone marrow derived osteoblasts in the Management of Avascular Necrosis of the Head of Femur: A Phase II
Autologous Bone Marrow Derived Chondrocytes in the Management of Osteoarthritis of Knee: A Phase II Clinical Trial. Read more about Autologous Bone Marrow Derived Chondrocytes in the Management of Osteoarthritis of Knee: A Phase II Clinical Trial.
An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma "(EVERMORE). Read more about An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma "(EVERMORE).
"An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children ≤ 5 Years of Age with Hypophosphatasia (HPP). " Read more about "An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children ≤ 5 Years of Age with Hypophosphatasia (HPP). "
An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency Read more about An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
A two part seamless, open label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy. Read more about A two part seamless, open label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy.
A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole. Read more about A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole.
